- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00524316
Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
A Phase II Study of SUNITINIB MALATE (Sutent) and Chemoembolization in Patients With Unresectable Hepatocellular Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Chemoembolization kills tumor cells by blocking the blood flow to the tumor and keeping chemotherapy drugs, such as doxorubicin, near the tumor. Giving sunitinib together with chemoembolization may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving sunitinib together with chemoembolization works in treating patients with liver cancer that cannot be removed by surgery.
Study Overview
Status
Conditions
Detailed Description
OBJECTIVES:
Primary
- To determine the progression-free survival at 4 months of patients treated with this regimen.
Secondary
- To determine overall survival of these patients.
- To determine if dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) can be used to measure decrease in tumor perfusion and vascular permeability as a result of treatment with sunitinib malate in combination with TACE, and if it can be useful in prognosis.
- To examine the safety and tolerability of this regimen.
- To determine if a change in circulating endothelial precursor cell number and total monocyte count on days 3, 8, 10, and 35 of therapy (as compared with levels at baseline) and decrease in soluble vascular endothelial growth factor receptor-2 in serum on days 8 (before TACE), 10, and 35 of therapy (as compared with baseline) correlate with improved response and survival.
- To determine the effect of this therapy on quality of life as measured by the FACT-HEP scale prior to each course of therapy.
OUTLINE: This is a multicenter study.
Patients receive oral sunitinib malate once daily on days 1-7 and 15-35 in course 1 and on days 1-28 in all subsequent courses. Patients undergo hepatic artery chemoembolization with doxorubicin hydrochloride on day 8 of course 1 only. Treatment with sunitinib malate repeats every 6 weeks* in the absence of disease progression or unacceptable toxicity.
NOTE: *Course 1 is 7 weeks in duration; all subsequent courses are 6 weeks in duration.
Blood samples are collected at baseline and periodically during study to measure circulating endothelial precursor cell levels, total monocyte count, and soluble vascular endothelial growth factor receptor-2.
Quality of life is assessed by the FACT-HEP scale at baseline, prior to each course of treatment, and then at the completion of treatment.
After completion of study treatment, patients are followed every 6 months.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New York
-
Buffalo, New York, United States, 14263-0001
- Roswell Park Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Histologically, cytologically, or serologically* confirmed hepatocellular carcinoma meeting the following criteria:
- 1-4 lesions
- Involvement of 1 or both liver lobes NOTE: *Alpha-fetoprotein (AFP) > 500 mcg/L in high-risk patients
Measurable disease by CT scan or MRI
- Disease does not exceed 50% of the liver parenchyma
- At least 1 lesion ≥ 3 cm in longest diameter
- Tumor burden involves < 50% of the liver
Refused surgery OR unresectable disease due to any of the following:
- Multifocality
- Advanced cirrhosis
- Comorbid illness
- Candidate for chemoembolization
- No fibrolamellar histology
- No ascites
- No known brain metastases
PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- Life expectancy ≥ 12 weeks
- WBC ≥ 3,000/mm³
- ANC ≥ 1,500/mm³
- Hemoglobin ≥ 8.5 g/dL (transfusion allowed)
- Platelet count ≥ 100,000/mm³
- Bilirubin ≤ 2 mg/dL
- AST ≤ 5 times upper limit of normal (ULN)
- INR < 1.5
- Creatinine ≤ 2.0 mg/dL OR creatinine clearance ≥ 30 mL/min
- No bleeding diathesis or coagulopathy
- No active congestive heart failure
- No uncontrolled angina
- No myocardial infarction within the past 12 months
- No cardiac arrhythmia
- Ejection fraction ≥ 45% (in patients with known coronary artery disease and in patients > 50 years of age)
- Child-Pugh class A or B cirrhosis
- No impedance of hepatopedal blood flow (portal vein thrombosis)
- No thrombosis of the main portal vein
- No encephalopathy
- No biliary obstruction
- No variceal bleed within the past 6 months
- No history of allergic reactions attributed to compounds of similar chemical or biologic composition to sunitinib malate
- No absolute contraindication to doxorubicin, iodinated contrast material, microfibrillar collage hemostat, or dexamethasone
No other concurrent uncontrolled illness including, but not limited to, any of the following:
- Ongoing or active infection
- Psychiatric illness or social situation that would limit compliance with study requirements
- No other active malignancies within the past year except nonmelanoma skin cancer or carcinoma in situ
- No significant traumatic injury within the past 4 weeks
- No QTc prolongation (i.e., QTc interval ≥ 500 msec) or other significant ECG abnormalities
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 6 months after the completion of study treatment
PRIOR CONCURRENT THERAPY:
- Recovered from prior therapy
Prior liver-directed therapy, such as chemoembolization, radiofrequency ablation, cryoablation, or ethanol injection allowed if the following criteria are met:
- Treated lesion remains inactive by CT scan or MRI and new lesion being embolized is distinct from the previously treated lesion
- Radiographic progression of previously treated lesion requiring re-embolization
- Prior liver resection allowed
- Prior immunotherapy allowed
- No prior antiangiogenesis therapy
No prior liver transplantation
- Patients awaiting a cadaveric or orthotopic liver transplantation are eligible provided they have end-stage liver disease with a priority score of < 20 points
- More than 4 weeks since prior radiotherapy or chemotherapy (6 weeks for nitrosoureas or mitomycin C)
- More than 4 weeks since prior major surgery or open biopsy
- At least 1 week since prior fine needle biopsy
- No concurrent immunotherapy
- No concurrent radiotherapy
- No concurrent combination antiretroviral therapy for HIV-positive patients
No concurrent therapeutic doses of coumarin-derivative anticoagulants (e.g., warfarin)
- Doses of ≤ 1 mg/day are allowed for prophylaxis of thrombosis as long as INR ≤ 1.5
- Both full dose and prophylactic dose low molecular weight heparin allowed as long as PT INR ≤ 1.5
- No anticipated major surgery during and for 3 months after completion of study treatment
- No other concurrent investigational agents
- No other concurrent anticancer therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sunitinib
oral sunitinib malate once daily on days 1-7 and 15-35 in course 1 and on days 1-28 in all subsequent courses
|
Correlative Study
Correlative Study
Transarterial chemoembolization
Given Orally
Surgical procedure
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free Survival
Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
|
median progression free survival in months
|
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival
Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
|
median survival in months
|
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
|
Tissue Perfusion, Ktrans, IAUC, and Percent Viable Tumor as Measured by DCE-MRI at Baseline and on Days 8 (Before Transarterial Chemoembolization), 10, and 35
Time Frame: Baseline, day 8, day 10, day 28 and day 35
|
Baseline, day 8, day 10, day 28 and day 35
|
|
Safety and Tolerability
Time Frame: Daily while on treatment through study completion, an average of 1 year
|
Number of participants with adverse advent. Please refer to adverse event reporting for more detail. |
Daily while on treatment through study completion, an average of 1 year
|
Assess the Change in the Quality of Life Among Patients Using the FACTHep (Version 4) for Hepatobiliary Cancers.
Time Frame: Baseline and Cycle 2
|
We utilized the FACT-HEP TOTAL SCORE (version 4) quality-of-life scale, which is a 45 item scale ranging from 96-178. Higher scores reflect better quality of life. No subscales were analyzed. |
Baseline and Cycle 2
|
Tumor Marker Response (AFP)
Time Frame: Baseline, week 7 and every 6 weeks after
|
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
|
Baseline, week 7 and every 6 weeks after
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Renuka Iyer, MD, Roswell Park Cancer Institute
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Digestive System Neoplasms
- Liver Diseases
- Liver Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Protein Kinase Inhibitors
- Antibiotics, Antineoplastic
- Sunitinib
- Doxorubicin
- Liposomal doxorubicin
Other Study ID Numbers
- CDR0000563261
- RPCI-I-82706
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Cancer
-
Slawa CwajnaNova Scotia Health AuthorityWithdrawnPrimary Liver Cancer | Metastatic Liver CancerCanada
-
Duke UniversityCompletedPrimary Liver Cancer | Metastatic Liver Cancer From Any Cancer SiteUnited States
-
University of HawaiiGlaxoSmithKlineRecruitingAdvanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Adult Primary Liver CancerUnited States
-
Célia TurcoCompletedPrimary Liver Cancer | Liver Metastases | Secondary Liver CancerFrance
-
University of CincinnatiActive, not recruitingLiver Metastases | Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver CancerUnited States
-
Lisa H. Butterfield, Ph.D.National Cancer Institute (NCI)TerminatedHepatocellular Carcinoma | Liver Cancer | Cancer of Liver | Hepatoma | Hepatocellular Cancer | Hepatic Cancer | Liver Cell Carcinoma | Cancer, Hepatocellular | Liver Cancer, Adult | Liver Cell Carcinoma, Adult | Cancer of the Liver | Neoplasms, Liver | Hepatic Neoplasms | Neoplasms, HepaticUnited States
-
Radboud University Medical CenterTerumo Medical CorporationCompletedPrimary Liver Cancer | Liver Cancer | Liver Metastasis Colon CancerNetherlands
-
Cardiovascular and Interventional Radiological...RecruitingPrimary Liver Cancer | Secondary Liver CancerGermany
-
Shanghai Huihe Medical Technology Co., LtdEnrolling by invitation
-
Burzynski Research InstituteTerminatedPrimary Liver CancerUnited States
Clinical Trials on laboratory biomarker analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States